Final FDA Waiver Guidance For Point-Of-Care Diagnostics Unduly Burdensome, Industry Org. Says
This article was originally published in The Pink Sheet Daily
Long-awaited FDA guidance for point-of-care diagnostics to be used in less-sophisticated settings offers leeway in clinical trial design but not enough for industry.
You may also be interested in...
A small number of start-ups are developing novel specilalty-focused diagnostics that capture drug-like revenues and margins without taking drug-like development and regulatory risks. Questions about the business model abound, since most companies need multiple tests to reach profitability and a changing regulatory climate may force these companies to seek FDA approval for their tests, dramatically increasing development risk and cost.
ORA sets a 2012 priority of improving the efficiency of the recall process to help reach its overall enforcement and compliance goal of preventing public health emergencies.
In a report on best practices for guidance development, FDA encourages outside groups to submit their own draft guidance proposals to help make the overall process more efficient.